# EDGAR Filing Document

**Accession Number:** 0001831942
**File Stem:** 0001831942-25-000018
**Filing Date:** 2025-8
**Character Count:** 12842
**Document Hash:** 95fbfd0ceeaf37e18c0e2443bf6af0f1
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001831942-25-000018.hdr.sgml**: 20250828

**ACCESSION NUMBER**: 0001831942-25-000018

**CONFORMED SUBMISSION TYPE**: N-PX

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20250630

**FILED AS OF DATE**: 20250828

**EFFECTIVENESS DATE**: 20250828

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Commodore Capital LP
- **CENTRAL INDEX KEY:** 0001831942

**ORGANIZATION NAME:**
- **EIN:** 832659606
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** N-PX
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 028-20976
- **FILM NUMBER:** 251273286

**BUSINESS ADDRESS:**
- **STREET 1:** 444 MADISON AVENUE
- **STREET 2:** 35TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10022
- **BUSINESS PHONE:** 212-256-8600

**MAIL ADDRESS:**
- **STREET 1:** 444 MADISON AVENUE
- **STREET 2:** 35TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10022

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** COMMODORE CAPITAL LP
- **DATE OF NAME CHANGE:** 20201110

## FORM N-PX
### ANNUAL REPORT OF PROXY VOTING RECORD

## N-PX: Filer Information

**Filer CIK:** 0001831942

**Date of Report:** 06/30/2025

**Are you a Registered Management Investment Company or an Institutional Manager?:** Institutional Manager

**Is this a LIVE or TEST Filing?:** LIVE

**Is this an electronic copy of an official filing submitted in paper format?:** [ ]

### Submission Contact Information
_Not provided in this filing._

### Notification Information
**Notify via Filing Website only?:** [ ]

## N-PX: Cover Page

**Name of reporting person:** Commodore Capital LP

**Address:** 444 Madison Avenue, Floor 35, New York, NY 10022

**Telephone number:** 212-256-8600

**Name of agent for service:** —

**Agent Address:** —, —, — —

**Reporting Period:** Report for the year ended 06/30/2025

**SEC File Number:** 028-20976

**CRD Number (if any):** —

**Other SEC File Number (if any):** —

**LEI (if any):** 549300729275T4UVFT94

**Report Type (check only one):**

Institutional Manager.

- [x] Institutional Manager Voting Report

- [ ] Institutional Manager Notice Report

- [ ] Institutional Manager Combination Report

Registered Management Investment Company.

- [ ] Fund Voting Report

- [ ] Fund Notice Report

**Do you wish to provide explanatory information pursuant to Special Instruction B.4?:**

- [x] No

- [ ] Yes

**Additional information:** —

## N-PX: Summary - Included Managers

**Number of Included Institutional Managers:** 0

**Included Institutional Managers:** —

## FORM N-PX PROXY VOTING RECORD

| NAME OF ISSUER                   | CUSIP     | MEETING DATE   | VOTE DESCRIPTION                                                                                                                                            | VOTE CATEGORY                |     SHARES VOTED |   SHARES ON LOAN | HOW VOTED   |   SHARES VOTED FOR OR AGAINST MANAGEMENT | FOR OR AGAINST MANAGEMENT   | OTHER INFO   |
|:---|:---|:---|:---|:---|---:|---:|:---|---:|:---|:---|
| Immunovant, Inc.                 | 45258J102 | 08/12/2024     | To approve, on a non-binding, advisory basis, the compensation of our named executive officers.                                                             | SECTION 14A SAY-ON-PAY VOTES | 750990           |                0 | FOR         |                         750990           | FOR                         |  |
| ARCA biopharma, Inc.             | 687604108 | 08/22/2024     | To approve, on an advisory basis, certain compensation arrangements for ARCA named executive  officers that are based on or otherwise relate to the Merger; | SECTION 14A SAY-ON-PAY VOTES | 414325           |                0 | FOR         |                         414325           | FOR                         |  |
| VistaGen Therapeutics, Inc.      | 92840H400 | 08/26/2024     | To approve, on a non-binding advisory basis, the compensation paid to the Company's Named Executive Officers.                                               | SECTION 14A SAY-ON-PAY VOTES |      1.575e+06   |                0 | FOR         |                              1.575e+06   | FOR                         |  |
| Rhythm Pharmaceuticals, Inc.     | 76243J105 | 09/18/2024     | Approval, on an advisory (non-binding) basis, of the compensation of the named executive officers of the Company.                                           | SECTION 14A SAY-ON-PAY VOTES | 700000           |                0 | FOR         |                         700000           | FOR                         |  |
| Celcuity Inc.                    | 15102K100 | 05/13/2025     | To approve, by a non-binding and advisory vote, compensation of the named executive officers.                                                               | SECTION 14A SAY-ON-PAY VOTES | 695650           |                0 | FOR         |                         695650           | FOR                         |  |
| Vera Therapeutics, Inc.          | 92337R101 | 05/14/2025     | To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement.                          | SECTION 14A SAY-ON-PAY VOTES |      2.225e+06   |                0 | FOR         |                              2.225e+06   | FOR                         |  |
| Vera Therapeutics, Inc.          | 92337R101 | 05/14/2025     | To indicate, on an advisory basis, the preferred frequency of stockholder advisory votes on the compensation of the Company's named executive officers.     | SECTION 14A SAY-ON-PAY VOTES |      2.225e+06   |                0 | ONE YEAR    |                              2.225e+06   | FOR                         |  |
| Nurix Therapeutics, Inc.         | 67080M103 | 05/19/2025     | To approve, a non-binding advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement.                   | SECTION 14A SAY-ON-PAY VOTES |      4.08558e+06 |                0 | FOR         |                              4.08558e+06 | FOR                         |  |
| Alkermes plc                     | G01767105 | 05/21/2025     | To approve, in a non-binding, advisory vote, the compensation of the Company's named executive officers.                                                    | SECTION 14A SAY-ON-PAY VOTES |      1.825e+06   |                0 | FOR         |                              1.825e+06   | FOR                         |  |
| Merus N.V.                       | N5749R100 | 05/21/2025     | Approval, on an advisory (non-binding) basis, of the compensation of Merus N.V.'s named executive officers.                                                 | SECTION 14A SAY-ON-PAY VOTES |      3.98197e+06 |                0 | FOR         |                              3.98197e+06 | FOR                         |  |
| SCHOLAR ROCK HOLDING CORPORATION | 80706P103 | 05/22/2025     | To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers.                                                   | SECTION 14A SAY-ON-PAY VOTES |      1.745e+06   |                0 | FOR         |                              1.745e+06   | FOR                         |  |
| Spyre Therapeutics, Inc.         | 00773J202 | 05/29/2025     | To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers.                                                   | SECTION 14A SAY-ON-PAY VOTES |      1.01029e+06 |                0 | FOR         |                              1.01029e+06 | FOR                         |  |
| Oruka Therapeutics, Inc.         | 687604108 | 06/02/2025     | To approve, on a non-binding, advisory basis, the compensation of our named executive officers.                                                             | SECTION 14A SAY-ON-PAY VOTES |      1.40373e+06 |                0 | FOR         |                              1.40373e+06 | FOR                         |  |
| Oruka Therapeutics, Inc.         | 687604108 | 06/02/2025     | To vote, on a non-binding, advisory basis, on the frequency of future advisory votes to approve compensation for our named executive officers.              | SECTION 14A SAY-ON-PAY VOTES |      1.40373e+06 |                0 | ONE YEAR    |                              1.40373e+06 | FOR                         |  |
| Cogent Biosciences, Inc.         | 19240Q201 | 06/04/2025     | Approval, on a non-binding, advisory basis, of the compensation of the Company's named executive officers.                                                  | SECTION 14A SAY-ON-PAY VOTES |      8.14716e+06 |                0 | FOR         |                              8.14716e+06 | FOR                         |  |
| Xenon Pharmaceuticals Inc.       | 98420N105 | 06/04/2025     | To approve, on an advisory basis, the compensation of the Corporation's named executive officers;                                                           | SECTION 14A SAY-ON-PAY VOTES |      2.375e+06   |                0 | FOR         |                              2.375e+06   | FOR                         |  |
| Celldex Therapeutics, Inc.       | 15117B202 | 06/05/2025     | To approve, on an advisory basis, the compensation of the Company's Named Executive Officers as disclosed in this Proxy Statement.                          | SECTION 14A SAY-ON-PAY VOTES |      3.68e+06    |                0 | FOR         |                              3.68e+06    | FOR                         |  |
| Neurogene, Inc.                  | 64135M105 | 06/12/2025     | To approve on an an (non-binding) basis the compensation of the Company's named executive officers.                                                         | SECTION 14A SAY-ON-PAY VOTES | 925000           |                0 | FOR         |                         925000           | FOR                         |  |
| Solid Biosciences Inc.           | 83422E204 | 06/12/2025     | The approval of an advisory vote on executive compensation.                                                                                                 | SECTION 14A SAY-ON-PAY VOTES |      5.825e+06   |                0 | FOR         |                              5.825e+06   | FOR                         |  |
| Apogee Therapeutics, Inc.        | 03770N101 | 06/17/2025     | Vote on the frequency of future advisory votes to approve our named executive officers compensation.                                                        | SECTION 14A SAY-ON-PAY VOTES | 290000           |                0 | ONE YEAR    |                         290000           | FOR                         |  |
| Avalo Therapeutics, Inc.         | 05338F306 | 06/17/2025     | To approve, on a nonbinding advisory basis, a "Say-on-Pay" resolution regarding the compensation of our named executive officers;                           | SECTION 14A SAY-ON-PAY VOTES | 483000           |                0 | FOR         |                         483000           | FOR                         |  |
| Agios Pharmaceuticals, Inc.      | 00847X104 | 06/18/2025     | To vote, on an advisory basis, to approve the compensation paid to our named executive officers.                                                            | SECTION 14A SAY-ON-PAY VOTES |      2.29164e+06 |                0 | FOR         |                              2.29164e+06 | FOR                         |  |
| Nuvalent, Inc.                   | 670703107 | 06/18/2025     | To approve, on an advisory basis, the compensation paid to our named executive officers.                                                                    | SECTION 14A SAY-ON-PAY VOTES |      1.805e+06   |                0 | FOR         |                              1.805e+06   | FOR                         |  |
| Viridian Therapeutics, Inc.      | 92790C104 | 06/20/2025     | To approve, on an advisory basis, the compensation of the Company's named executive officers.                                                               | SECTION 14A SAY-ON-PAY VOTES |      5.25e+06    |                0 | AGAINST     |                              5.25e+06    | AGAINST                     |  |
| Cardiff Oncology, Inc.           | 14147L108 | 06/26/2025     | Proposal to approve, on an advisory basis, the compensation of the Company's named executive officers.                                                      | SECTION 14A SAY-ON-PAY VOTES |      1.25e+06    |                0 | FOR         |                              1.25e+06    | FOR                         |  |

## N-PX: Signature Block

**Reporting Person:** Commodore Capital LP

**By (Signature):** Michael Kramarz

**By (Printed Signature):** Michael Kramarz

**By (Title):** Managing Partner

**Date:** 08/28/2025